Dead Bifidobacterium Breve for Stable Cholesterol Binding

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing probiotic agents, particularly live lactic acid bacteria, face challenges with stability and efficacy due to acid and bile tolerance issues in the digestive tract, leading to inconsistent physiological activity and potential side effects, while dead cell technologies require high specificity in methods and types for effective cholesterol reduction.

Innovation Solution

A novel Bifidobacterium breve IDCC 4401 strain and its dead cell form, ID-BBR4401, exhibit excellent acid and bile tolerance, providing superior cholesterol and bile acid binding abilities, effectively reducing cholesterol and triglycerides in vivo.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If live probiotic cells are used for dyslipidemia treatment, then therapeutic effect is achieved, but stability in digestive environment deteriorates and side effects occur

Engineering Contradiction:

Improvetherapeutic effect stabilityVSAvoidacid and bile tolerance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs dead cell probiotics instead of live cells. The dead cells maintain their cholesterol-binding capability without the instability issues of live cells in the digestive environment, eliminating side effects while preserving therapeutic effect. This represents a paradigm shift from using living organisms to using their functional remnants.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent extracts the essential functional property (cholesterol binding) from the live cell structure through heat treatment, creating dead cells that retain the therapeutic function without the biological activity that causes instability. The functional essence is separated from the problematic living state.

Inventive Principle:

Principle #2Taking out (Extraction)

2Reliability

If live probiotic cells are used, then cholesterol-binding ability is maintained, but storage stability deteriorates

Engineering Contradiction:

Improvecholesterol-binding abilityVSAvoidstorage stability

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

Dead cells provide superior storage stability compared to live cells. Once the cells are heat-treated and deactivated, they maintain their structural integrity and cholesterol-binding capability throughout storage without the metabolic activities that degrade live cells. This resolves the contradiction between maintaining function and ensuring storage stability.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Reliability

If statin-based drugs are used for dyslipidemia treatment, then cholesterol synthesis is inhibited, but side effects increase

Engineering Contradiction:

Improvecholesterol reduction effectVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent uses dead cell probiotics as an alternative to statin drugs. The dead cells bind cholesterol in the intestine through their cell wall structures, providing cholesterol reduction without the systemic side effects associated with statin medications. This represents a natural, non-invasive approach to dyslipidemia treatment.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The dead cell probiotics act as an intermediary substance that binds cholesterol in the gastrointestinal tract, preventing its absorption. This intermediary mechanism avoids the direct interference with cholesterol synthesis enzymes that causes statin side effects, while achieving similar therapeutic outcomes.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

ID-BBR4401 demonstrates stable and high-level cholesterol reduction, particularly lowering LDL-cholesterol and triglycerides, offering a safe and effective therapeutic approach for dyslipidemia without side effects.

Implementation Method 1

The Bifidobacterium breve IDCC 4401 strain (accession number: KCTC13169BP) or dead cell thereof ID-BBR4401... demonstrate superior cholesterol-lowering effects

Methodology Applied

Scientific EffectAdsorption: Adsorption

Implementation Method 2

a dead cell form, ID-BBR4401... maintaining cholesterol-binding ability even after heat treatment

Methodology Applied

Scientific EffectHeat treatment: Heat Treatment

Data Source

PatentUS12616725B2<i>Bifidobacterium breve </i>IDCC 4401 strain and its dead cell ID-BBR4401 having excellent acid tolerance and bile tolerance and prophylactic or therapeutic effect on dyslipidemia

Publication Date: 2026.05.05 ILDONG HEALTHCARE

AI summary

The present invention relates to a novel Bifidobacterium breve IDCC 4401 strain (accession number: KCTC13169BP) and dead cell thereof ID-BBR4401, which are superb in acid tolerance and bile tolerance and have a preventive or therapeutic effect on dyslipidemia. Having not only an excellent effect of reducing a cholesterol level in the body but alto a very high level of acid tolerance and bile tolerance in contrast to previously known B. breve, the novel Bifidobacterium breve IDCC 4401 strain (accession number: KCTC13169BP) of the present invention well exhibits the functionality that the strain has in the digestive duct of animals (especially humans), has an excellent growth potential, and provides sustainable and effective functionality of reducing a level of cholesterol in vivo.